| 罗 静,王 红,王春佟,李 硕,宫变荣.昂丹司琼联合泮托拉唑对宫颈癌同步放化疗所致恶心呕吐的临床疗效[J].现代生物医学进展英文版,2020,(24):4735-4738. |
| 昂丹司琼联合泮托拉唑对宫颈癌同步放化疗所致恶心呕吐的临床疗效 |
| Effect of Ondansetron Combined with Pantoprazole on the Nausea and Vomiting in Cervical Cancer Caused by Concurrent Chemoradiotherapy |
| Received:July 02, 2020 Revised:July 25, 2020 |
| DOI：10.13241/j.cnki.pmb.2020.24.030 |
| 中文关键词: 昂丹司琼 泮托拉唑 宫颈癌 同步放化疗 恶心呕吐 |
| 英文关键词: Ondansetron Pantoprazole Cervical Cancer Concurrent Chemoradiotherapy Nausea And Vomiting |
| 基金项目:国家自然科学基金青年基金项目(81502038) |
|
| Hits: 693 |
| Download times: 459 |
| 中文摘要: |
| 摘要 目的：研究昂丹司琼联合泮托拉唑对宫颈癌同步放化疗所致恶心呕吐的临床疗效。方法：选择2018年1月～2020年1月我院收治的79例宫颈癌患者，均采取同步化疗，将其随机分为两组。对照组在当天化疗前30 min和随后的6 d连续静脉注射昂丹司琼，每次8 mg，1次/d；同时给予地塞米松磷酸钠注射液10 mg，1次/d。观察组在昂丹司琼的基础上静脉注射泮托拉唑，每次40 mg，1次/d，给药的时间与昂丹司琼相同。比较两组宫颈癌患者恶心呕吐的完全缓解率、癌因性疲乏评分和不良反应的发生情况。结果：两组化疗第1、2 d恶心呕吐的完全缓解率比较差异无明显统计学意义(P>0.05)，观察组化疗第3、4、5、6 d恶心呕吐的完全缓解率分别为76.92 %、79.49 %、87.18 %、87.18 %，均明显高于对照组(P<0.05)；观察组的癌因性疲乏评分为(45.39±7.29)分，明显低于对照组的(67.24±8.36)分(P<0.05)；两组的乏力嗜睡、便秘、椎体外系反应、失眠/不安、腹泻、轻度头痛的发生率比较无明显统计学差异(P>0.05)。结论：昂丹司琼联合泮托拉唑对宫颈癌同步放化疗所致恶心呕吐的疗效显著优于单用昂丹司琼治疗，并能明显减轻癌因性疲乏，且安全性高。 |
| 英文摘要: |
| ABSTRACT Objective: To study the clinical efficacy of ondansetron combined with pantoprazole on nausea and vomiting caused by concurrent chemoradiotherapy of cervical cancer. Methods: 79 cases if patients with cervical cancer who were treated in our hospital from January 2018 to January 2020 were selected for concurrent chemotherapy, and they were randomly divided into two groups. The control group was given intravenous injection of ondansetron, 8 mg each time, once per day at 30 minutes before chemotherapy and the following 6 days. At the same time, dexamethasone sodium phosphate injection 10 mg was given once daily. In the observation group, intravenous pantoprazole was given on the basis of ondansetron, 40 mg each time, once per day, and the administration time was the same as ondansetron. The complete remission rate of nausea and vomiting, cancer-related fatigue score and the incidence of adverse reactions between the two groups. Results: There was no significant difference in the complete remission rate of nausea and vomiting between the two groups on the first, second day of chemotherapy (P>0.05). The complete remission rate of nausea and vomiting on the 3rd, 4th, 5th and 6th day of chemotherapy in the observation group were 76.92 %,79.49 %, 87.18 %, 87.18 %, respectively, all significantly higher than those in the control group (P<0.05). The score of cancer-related fatigue in the observation group was (45.39±7.29), which was significantly lower than that in the control group (67.24±8.36, P<0.05). There was no significant difference in the incidence of asthenia, sleepiness, constipation, extravertebral reaction, insomnia / restlessness, diarrhea and mild headache between the two groups (P>0.05). Conclusion: Ondansetron combined with pantoprazole not only had a significant effect on nausea and vomiting caused by concurrent chemoradiotherapy of cervical cancer, but also could significantly reduce cancer-related fatigue with high safety. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
